The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
Open accessAbstract
Gastric cancer (GC) is the fourth leading cause of death worldwide, with more than 1 million cases diagnosed every year. Helicobacter pylori represents the main risk factor, being responsible for 78% of the cases. Increased amounts of salt, pickled food, red meat, alcohol, smoked food, and refined sugars negatively affect the stomach wall, contributing to GC development. Several gene mutations, including PIK3CA, TP53, ARID1A, CDH1, Ras, Raf, and ERBB3 are encountered in GC pathogenesis, leading to phosphatidylinositol 3-kinase (PI3K) protein kinase B (AKT)/mammalian target of rapamycin (mTOR)—PI3K/AKT/mTOR—and mitogen-activated protein kinase (MAPK) signaling pathway activation and promoting tumoral activity. Helicobacter pylori, growth factors, cytokines, hormones, and oxidative stress also activate both pathways, enhancing GC development. In clinical trials, promising results have come from monoclonal antibodies such as trastuzumab and ramucirumab. Dual inhibitors targeting the PI3K/AKT/mTOR and MAPK signaling pathways were used in vitro studies, also with promising results. The main aim of this review is to present GC incidence and risk factors and the dysregulations of the two protein kinase complexes together with their specific inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · cited 1×
“MAPK has three major subfamilies: the first includes the extracellular-signal-regulated kinases (ERK MAPK); the second includes the c-jun N-terminal kinase or stress-activated protein kinases (JNK or SAPK); and the last includes MAPK14 [125].”
BackgroundIs gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035
Arnold, M., Park, J. Y., Camargo, M. C., Lunet, N., Forman, D., & Soerjomataram, I. (2020) · Gut · doi:10.1136/gutjnl-2019-320234 · Cited by 504 · cited 1×
“Australia also has a decreased rate of GC [17].”
BackgroundOncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355 · cited 1×
“Besides the catalytic subunit of Class IA PI3K, other compounds such as the Class IA p85 α -regulatory subunit, AKT, mTOR, and eukaryotic translation initiation factor 4E (eIF4E) possess oncogenic potential [148].”
BackgroundSelectivity of Docking Sites in MAPK Kinases
Bardwell, A. J., Frankson, E., & Bardwell, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900080200 · Cited by 127
Chen, M., Lu, J., Wei, W., Lv, Y., Zhang, X., Yao, Y., Wang, L., Ling, T., & Zou, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161198 · Cited by 61
Cited by
Helicobacter pylori and gastric cancer: mechanisms and new perspectives
Duan, Y., Xu, Y., Dou, Y., & Xu, D. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01654-2 · Cited by 300
Metadata
- Authors
- Morgos, D.-T., Stefani, C., Miricescu, D., Greabu, M., Stanciu, S., Nica, S., Stanescu-Spinu, I.-I., Balan, D. G., Balcangiu-Stroescu, A.-E., Coculescu, E.-C., Georgescu, D.-E., & Nica, R. I.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-02-03
- Volume
- 25
- Issue
- 3
- Pages
- 1848
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4391539991
- Cited by
- 176
- References
- 6
- FWCI
- 20.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer. https://app.cochat.ai/papers/10.3390/ijms25031848
- The paper
- Morgos, D.-T., Stefani, C., Miricescu, D., Greabu, M., Stanciu, S., Nica, S., Stanescu-Spinu, I.-I., Balan, D. G., Balcangiu-Stroescu, A.-E., Coculescu, E.-C., Georgescu, D.-E., & Nica, R. I. (2024). Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.